Trial · NCT03489044
An Investigation of Levetiracetam in Alzheimer's Disease
NCT03489044, Phase 2, Completed, University of Oxford
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Investigation of Levetiracetam in Alzheimer's Disease. Trials, record NCT03489044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03489044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Investigation of Levetiracetam in Alzheimer's Disease
- NCT number
- NCT03489044
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- University of Oxford
- Conditions
- Alzheimer Disease, Epilepsy
- Interventions
- Levetiracetam, Placebo Oral Tablet
- First posted
- 2018-04-05
- Last updated
- 2024-04-24
- Other registries' IDs
- eudract:2016-003109-32
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of Levetiracetam on hippocampal function in patients with Alzheimer's disease as assessed by a computerised test of hippocampal binding | 18 months | Change from baseline in measures of hippocampal binding on a standardised computer based test. Participants will be shown fractals on a screen, followed by a blank screen. The participants will be then shown one of the fractals they saw previously and a foil. The participants will have to identify which of the fractals they saw initially and then drag that fractal on the screen to the location where it appeared before. The computer will assess whether the participant correctly identifies which fractal had been seen previously and also assess how accurately the participant remembers the location of the previously shown fractal. The investigators will then evaluate whether there are any changes in the accuracy of remembering fractals/fractal position after exposure to Levetiracetam/placebo |
| Secondary | Number of participants with treatment related serious adverse events as reported on the serious adverse events proforma | 18 months | To determine if use of Levetiracetam associates with significant side effects in patients with AD that have not experienced an overt seizure |
| Secondary | Effect of Levetiracetam on mood in patients with Alzheimer's disease | 18 months | Number of participants reporting change from baseline on the Neuropsychiatric Inventory |
| Secondary | Effect of Levetiracetam on quality of life in patients with Alzheimer's disease as assessed by their principal carer | 18 months | Number of participants with a change from baseline on Dementia Severity Rating Scale |
| Secondary | Effect of Levetiracetam on quality of life in patients with Alzheimer's disease | 18 months | Number of participants with a change from baseline on the Euro-QoL (EQ5D) measure |
| Secondary | Determining role of the electroencephalogram in patients with Alzheimer's disease | 18 months | Correlation of electroencephalogram recording with effect of Levetiracetam on cognition as assessed by a computer based test of hippocampal binding |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03489044
GET https://conductscience.org/api/trials/v1/NCT03489044/registered